**Question**: Should EndoBarrier® vs. non-surgical management be used for weight loss?

Certainty assessment							№ of patients		Effect			
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Endobarrier	non-surgical management	Relative (95% CI)	Absolute (95% CI)	Certainty	Importance
%EWL (follow up: mean 9.2 months)												
4	randomised trials	not serious	not serious	not serious	serious <sup>a</sup>	none	301		-	MD <b>36.9</b> % <b>more</b> (29.2 more to 44.6 more)	⊕⊕⊕⊖ MODERATE	CRUCIAAL
mprovem	ent in %HbA1c	(follow up: r	mean 8.4 month	s)	1							T
14	observational studies	serious <sup>b</sup>	serious <sup>c</sup>	not serious	not serious	publication bias strongly suspected d	388		-	MD <b>1.29</b> % <b>more</b> (0.97 more to 1.62 more)	⊕○○ VERY LOW	BELANGRIJK
1orbidity	(follow up: me	an 1 years)	•		-							
3	randomised trials	not serious	not serious	not serious	very serious e	none	12/54 (22.2%)	0/47 (0.0%)	<b>OR 0.27</b> (0.13 to 0.41)	O fewer per 1.000 (from 0 fewer to 0 fewer)	⊕⊕○○ Low	CRUCIAAL

CI: Confidence interval; MD: Mean difference; OR: Odds ratio